FDA Orange Book
Is there a generic for Zilretta?
Zilretta contains triamcinolone acetonide. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zilretta (triamcinolone acetonide). The Orange Book shows its last listed patent expires August 4, 2031.
Run it in Rivvi
Map Zilretta and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Zilretta products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| for suspension, extended release, intra-articular | 32MG/VIAL | Marketed (Rx) | None | 0 | None |
NDA 208845, held by PACIRA PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Zilretta patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 9555048 | August 4, 2031 | Method of use | U-2151 | 208845 |
| 8828440 | August 4, 2031 | Drug product | None | 208845 |
Questions
Is there a generic for Zilretta?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Zilretta (triamcinolone acetonide). The Orange Book shows its last listed patent expires August 4, 2031.
What is the generic name for Zilretta?
The active ingredient in Zilretta is triamcinolone acetonide, per the FDA Orange Book.
When does the Zilretta patent expire?
The last patent listed for Zilretta in the Orange Book expires August 4, 2031. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.